Phase 3 N=32 Early Treatment of Cytokine Storm Syndrome in Covid-19
Cytokine Storm · COVID-19
Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
Phase 3 N=46 Cytokine Removal in Cardiopulmonary Bypass Patients
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
N/A N=21 Inflammatory Cytokine Quantification in Infants
Sepsis · Congenital Diaphragmatic Hernia · Neonatal Cardiopulmonary Failure
Primary: TNF-alpha, Baseline — 8.88 pg/mL
N/A N=17 Cytokines in Papillon-Lefèvre Syndrome
Papillon-Lefevre Disease
Primary: Serum Concentrations of Interleukin (IL)-1 Beta — 1100.00; 896.21; 65559; 45734 pg/ml
N/A N=82 Cytokine Expression During Radiation for Breast Cancer
Breast Cancer
Primary: Number of Proteins Expressed Differently in Response to Receiving Radiation Therapy — 31 Proteins
Phase 2 N=178 A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
COVID-19
Primary: Ventilator Free Survival — 58; 19; 44 Participants
Phase 2 N=83 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
COVID-19 Pneumonia · Acute Lung Injury · ARDS
Primary: Number of Subjects Alive and Free of Respiratory Failure — 26; 20 Participants — p=0.0440
N/A N=40 Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis
Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 5040.638; 454.392 picogram/milliliter (pg/mL)
Phase 3 N=432 Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
Cytokine Storm (Covid-19)
Primary: Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care — 34; 17 Participants — p=0.769
Phase 4 N=16 Fluoxetine to Reduce Intubation and Death After COVID19 Infection
COVID-19 · Cytokine Storm
Primary: Number of Outpatient Subject Hospitalizations — 0; 0 Participants
N/A N=141 Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock
Cardiac Arrest
Primary: Survival Rate - Number of Participants Alive — 55; 20; 32; 34 Participants — p=<0.001
Phase 2 N=28 Duvelisib to Combat COVID-19
COVID-19
Primary: Overall Survival as Measured by Number of Participants Alive Through 28 Days — 10; 8 Participants
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
Phase 4 N=126 Fingolimod Effect on Cytokine and Chemokine Levels
Relapsing Remitting Multiple Sclerosis
Primary: Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA — 212.26; 404.31; 1.15; 1.06 pg/ml — p=0.000
Phase 3 N=342 Treatment of COVID-19 Patients With Anti-interleukin Drugs
COVID-19
Primary: Time to Clinical Improvement — 12; 12; 11; 12 days
Phase 3 N=1,971 Immune Modulators for Treating COVID-19
Covid19
Primary: Number of Participants Who Had Recovered by Day 28 — 421; 405; 414; 397 Participants — p=0.0793
Phase 2 N=228 CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…
Phase 2 N=81 Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
COPD Exacerbation
Primary: Number of Moderate to Severe Exacerbation (Defined as Requiring Treatment With Systemic Corticosteroids and/or Antibiotics in the Community or Hospital or…
Phase 3 N=1,032 Novel Experimental COVID-19 Therapies Affecting Host Response
COVID-19 · SARS-CoV-2 Infection · Coronavirus Infection
Primary: Oxygen Free Days Through Day 28. — 9.0; 11.3; 8.1; 10.5 Days
Phase 2 N=32 Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
COVID-19
Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants
Phase 4 N=103 Immune and Hormone Response to Influenza Vaccine
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml
Phase 2 N=45 Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
COVID-19 · SARS-CoV 2
Primary: Number of Participants With Clinical Improvement at Day 14 — 9; 7; 9 Participants
Phase 2 N=73 Cytokine Induced Killer (CIK) Cells In Leukemia Patients
Hematologic Malignancies
Primary: Safety Measures — 0 participants
Phase 3 N=73 MIS-C Comparative Effectiveness Study
Multisystem Inflammatory Syndrome-Children
Primary: Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization — 10; 10; 14 Participants
Phase 2 N=80 Anti-Cytokine Therapy for Hemodialysis InflammatION
End-Stage Renal Disease
Primary: Safety and Tolerability of Anakinra, for Patients Receiving Maintenance Hemodialysis — 2.71; 2.74 events per patient-year
N/A N=28 Short-Term Application of Tocilizumab Following Myocardial Infarction
Myocardial Infarction
Primary: Number of Participants With Major Adverse Cardiovascular Events (MACE) — 0; 0; 2; 1 Participants
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
N/A N=14 Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytoses
Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 2079.286; 15197.143 picogram/milliliter (pg/mL)
Phase 2 N=160 Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
Acute Lung Injury · Acute Respiratory Distress Syndrome · Respiratory Failure
Primary: Serum IL-6 Level — -0.79; -0.79 pg/mL